These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11101087)

  • 21. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of reverse transcriptase mutations associated with HIV-1 drug resistance mainly against non-nucleoside reverse transcriptase inhibitors in treatment-naive patients.
    Magiorkinis E; Paraskevis D; Lazanas M; Kiosses VG; Gargalianos P; Hatzakis A
    AIDS; 1999 Jul; 13(10):1276-8. PubMed ID: 10416535
    [No Abstract]   [Full Text] [Related]  

  • 23. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
    Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution of HIV-1 multidrug-resistant genotypes during combination therapy and after the cessation of antiretroviral drugs.
    Yahi N; Tourrès C; Tivoli N; Colson P; Dhiver C; Quinson AM; Tamalet C
    AIDS; 2000 Dec; 14(18):2943-5. PubMed ID: 11153678
    [No Abstract]   [Full Text] [Related]  

  • 28. Detection of resistant mutations in the reverse transcriptase of HIV-1-infected children.
    Palomares JC; Perea EJ; Terrero E; Torres MJ; García ML; Romero J; Alejo A
    Clin Microbiol Infect; 2000 May; 6(5):268-70. PubMed ID: 11168125
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.
    Duan C; Poticha D; Stoeckli TC; Petropoulos CJ; Whitcomb JM; McHenry CS; Kuritzkes DR
    J Infect Dis; 2001 Nov; 184(10):1336-40. PubMed ID: 11679926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reverse transcriptase fidelity and HIV-1 variation.
    Balzarini J; Pelemans H; De Clercq E; Karlsson A; Kleim JP
    Science; 1997 Jan; 275(5297):229-30; author reply 230-1. PubMed ID: 8999551
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.
    Garcia-Lerma JG; Nidtha S; Blumoff K; Weinstock H; Heneine W
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13907-12. PubMed ID: 11698656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reverse transcriptase fidelity and HIV-1 variation.
    Keulen W; Nijhuis M; Schuurman R; Berkhout B; Boucher C
    Science; 1997 Jan; 275(5297):229; author reply 230-1. PubMed ID: 8999550
    [No Abstract]   [Full Text] [Related]  

  • 35. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
    Rey D; Hughes M; Pi JT; Winters M; Merigan TC; Katzenstein DA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):203-8. PubMed ID: 9495218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective expansion of a minor proportion of drug-resistant HIV-1 by antiretroviral pressure in vitro.
    Roberts BD; Pau CP; Weinstock H; Heneine W; Butera ST
    AIDS; 2000 Dec; 14(17):2797-8. PubMed ID: 11125904
    [No Abstract]   [Full Text] [Related]  

  • 37. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
    Coakley EP; Gillis JM; Hammer SM
    AIDS; 2000 Jan; 14(2):F9-15. PubMed ID: 10708277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations in the reverse transcriptase gene of HIV type 1 from subjects after stavudine-didanosine dual therapy.
    Monno L; Appice A; Scarabaggio T; Di Stefano M; Pastore G; Angarano G
    AIDS Res Hum Retroviruses; 2000 May; 16(8):821-3. PubMed ID: 10826489
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.
    Calvez V; Costagliola D; Descamps D; Yvon A; Collin G; Cécile A; Delaugerre C; Damond F; Marcelin AG; Matheron S; Simon A; Valantin MA; Katlama C; Brun-Vézinet F
    Antivir Ther; 2002 Sep; 7(3):211-8. PubMed ID: 12487389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.